The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Asia 2023 | PERLA trial outcomes in global and Asian subgroup populations
Beung Chul Ahn, MD, National Cancer Center, Seoul, South Korea, summarizes the outcomes of the Phase II PERLA trial (NCT04581824), the first global double-randomized study comparing the efficacy of PD-1 inhibitors dostarlimab and pembrolizumab in patients with non-small cell lung cancer (NSCLC). Treatment was administered alongside chemotherapy (CT) and progression-free survival (PFS) measured as the primary endpoint. Subgroup analyses in Asian populations support the hypotheses of this trial, although small sample sizes support the requirement for further studies into dostarlimab and CT treatment. With immunotherapy and CT as the current first-line treatment, further studies combining and comparing this with dostarlimab should be considered. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
